Expert witness

Paul W. Hruz, M.D., Ph.D.

Pediatric endocrinology · testified for the side defending the laws

Across declarations, reports, and depositions filed from 2016 through 2024, Dr. Hruz consistently argues that pediatric gender dysphoria treatment with puberty blockers and cross-sex hormones is unapproved, insufficiently evidenced, and often irreversibly harmful, particularly to fertility and bone health. He maintains that most childhood gender dysphoria desists by late adolescence without medical intervention, that adolescents are neurodevelopmentally unable to give truly informed consent to such treatment, and that the professional guidelines endorsing it (Endocrine Society, WPATH) are the product of an advocacy-driven process rather than rigorous science. In his later reports (2022 onward) he adds a social-contagion/"rapid-onset gender dysphoria" explanation for the rise in adolescent, especially female, referrals, a theory largely absent from his earlier 2016 declarations. He also argues that claims linking affirming treatment to suicide prevention are unsupported, citing continued elevated suicidality in adult outcome studies. Long blocks of his analysis are reused nearly verbatim across different cases and years.

Cases and documents

The documents are listed as the archive holds them. A document labeled with its kind alone, such as "Expert report", is one the archive attributes to the expert. One labeled "Mentions or contains" names the expert or includes the expert's testimony, and is not attributed to the expert.

Boe v. Marshall M.D. Ala. · 2025

13 more documents

Carcaño v. McCrory M.D.N.C. · 2021

Dekker v. Weida 11th Cir. · 2026

  • Expert report: Exhibit Ex 13 Dr. Hruz Expert Report Open(opens another site) · In the case's documents
  • Trial testimony: PLAINTIFFS' MOTION TO EXCLUDE EXPERT TESTIMONY OF DR. PAUL W. HRUZ AND SUPPORTING MEMORANDUM OF LAW Open(opens another site) · In the case's documents
    19 attachments
    1. Exhibit Affidavit Declaration of Shani Rivaux
    2. Exhibit A - Hruz Report
    3. Exhibit B - Hruz Rebuttal Report
    4. Exhibit C - Deposition of Paul W Hruz
    5. Exhibit E - Videotaped Deposition of Paul W Hruz MD PhD
    6. Exhibit F - Deposition of Paul W Hruz MD PhD
    7. Exhibit G - Gender nonconforming youth current perspectives
    8. Exhibit Understanding the Well Being of LGBTQI and Populations (2020)
    9. Exhibit I - Understanding Unapproved Use of Approved Drugs Off Label
    10. Exhibit J - Off Label Use of Drugs in Children
    11. Exhibit K - Declaration of Norman P Spack MD
    12. Exhibit L - Telephonic Deposition of Kim G Hutton
    13. Exhibit M - International Conference on Gender Sex and Education in Madrid against the LGBTI doctrine
    14. Exhibit N - Journal Pre Proof
    15. Exhibit O - Remote Videotaped Videoconference Deposition Testimony of Patrick Lappert MD
    16. Exhibit P - Email from Endocrine Society to Omar Gonzalez Pagan
    17. Exhibit Q - Deposition Transcript of Dr Quentin Van Meter
    18. Exhibit R - Statement on Dr Kenneth Zucker and Gender Identity Disorder
    19. Exhibit S - APA Resolution on Gender Identity Change Efforts
  • Deposition: Exhibit Affidavit Declaration of Shani Rivaux Open(opens another site) · In the case's documents
  • Expert report: Exhibit A - Hruz Report Open(opens another site) · In the case's documents
  • Expert report: Exhibit B - Hruz Rebuttal Report Open(opens another site) · In the case's documents
  • Deposition: Exhibit C - Deposition of Paul W Hruz Open(opens another site) · In the case's documents
20 more documents
  • Deposition: Exhibit E - Videotaped Deposition of Paul W Hruz MD PhD Open(opens another site) · In the case's documents
  • Deposition: Exhibit F - Deposition of Paul W Hruz MD PhD Open(opens another site) · In the case's documents
  • Trial testimony: Exhibit K - FDA: Understanding Unapproved Use of Approved Drugs Off Label Open(opens another site) · In the case's documents
  • Trial testimony: Exhibit L - AAP: Policy Statement: Off-Label Use of Drugs in Children Open(opens another site) · In the case's documents
  • Trial testimony: AMENDED DOCUMENT by AUGUST DEKKER, JANE DOE, JOHN DOE, SUSAN DOE, K F, JADE LADUE, BRIT ROTHSTEIN. Amendment to 136 MOTION in Limine to Exclude Expert Testimony of Dr. Paul W. Hruz and Supporting Memorandum of Law TO IN… Open(opens another site) · In the case's documents
    1 attachment
    1. Exhibit Expert Witness Declaration of Paul W Hruz MD PhD
  • Declaration: Exhibit Expert Witness Declaration of Paul W Hruz MD PhD Open(opens another site) · In the case's documents
  • Deposition: Exhibit 90 - Deposition of Paul W. Hruz, Adams v. St. Johns, No. 3:17-cv-00739 Open(opens another site) · In the case's documents
  • Deposition: Exhibit 91 - Deposition of Paul W. Hruz, Bruce v. South Dakota, No. 17-5080 (USD Open(opens another site) · In the case's documents
  • Declaration: Exhibit 93 - Expert Declaration of Paul W. Hruz, Whitaker v. Kenosha, 2:16-cv-00 Open(opens another site) · In the case's documents
  • Deposition: Exhibit 94 - Deposition of Paul W. Hruz, Kadel v. Folwell, 1:19-cv-00272 (M.D. N Open(opens another site) · In the case's documents
  • Declaration: Exhibit 89 - Expert Declaration of Paul W. Hruz, Adams v. St. Johns, No. 3:17-cv Open(opens another site) · In the case's documents
  • Mentions or contains: deposition: Exhibit List (Notice of Filing, Part 2 of 10) Open(opens another site) · In the case's documents
    40 attachments
    1. Exhibit 41 - LGBT Health Disparities Policy, ACOP
    2. Exhibit 42 - AMA Letter to Natl Gov. Assoc. (April 26, 2021)
    3. Exhibit 43 - AMA/GLMA Issue Brief on health insurance coverage for gender-affirming care
    4. Exhibit 44 - AMA Resolution H-185.950
    5. Exhibit 45 - APA, Guidelines for Psychological Practice with Transgender and Gender Non-conforming People
    6. Exhibit 46 - APA Resolution on Gender Identity Change Efforts (Feb. 2021)
    7. Exhibit 47 - APA Position Statement Trans and Gender Diverse Youth (July 2020)
    8. Exhibit 48 - APA Position Statement on Access to Care (July 2018)
    9. Exhibit 49 - Endocrine Society Transgender Health Position Statement
    10. Exhibit 50 - Pediatric Endocrine Society Opposition to Bills that Harm Transgender Youth (April 2021)
    11. Exhibit 51 - SAHM Statement in Opposition of State Legislation Barring Evidence Based Treatment
    12. Exhibit 52 - WMA Statement on Transgender People (Oct. 2015)
    13. Exhibit 53 - Van Meter Pediatric Endocrinology Excerpt
    14. Exhibit 54 - Humana Pharmacy Coverage Policy, commercial insurance coverage policy for testosterone 5/18/2022
    15. Exhibit 55 - Aetna Clinical Policy Bulletin, coverage of Progestins 4/27/2023
    16. Exhibit 56 - Aetna, Clinical Policy Bulletin, gender affirming surgery 6/22/2023
    17. Exhibit 57 - Aetna, Clinical Policy Bulletin, GnRHa 2/23/2023
    18. Exhibit 58 - Humana, Medical Coverage Policy, cover of gender affirmation surgery 9/22/2022
    19. Exhibit 59 - Molina Healthcare, Coverage criteria for Gender Dysphoria Hormone Therapy July 2023
    20. Exhibit 60 - Molina Clinical Policy, Gender Affirmation Treatment and Procedures (Marketplace) - 2/8/2023
    21. Exhibit 61 - UHC Gender Dysphoria Treatment (commercial), 4/1/2023
    22. Exhibit 62 - Ctrs. for Medicare & Medicaid Servs., EPSDT A Guide for States: Coverage in the Medicaid Benefit for Children and Adolescents
    23. Exhibit 63 - Ctrs. for Medicare & Medicaid Servs., CMCS Informational Bulletin (July 21, 2022)
    24. Exhibit 64 - Ctrs. for Medicare & Medicaid Servs., Decision Memo for Gender Dysphoria and Surgery (Aug. 20, 2016)
    25. Exhibit 65 - Office of the Press Secretary, Presidential Memo (Aug. 25, 2017)
    26. Exhibit 66 - FDA, Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products (Draft Guidance) (2018)
    27. Exhibit 67 - FDA, Understanding Unapproved Use of Approved Drugs "Off Label," (2018)
    28. Exhibit 68 - U.S. Drug Enforcement Administration, Drug Scheduling, July 10, 2018
    29. Exhibit 69 - U.S. Comm. on Civil Rights Statement on State Laws Targeting LGBTQ Community, (April 18, 2016)
    30. Exhibit 70 - U.S. Comm. on Civil Rights Statement on Military Ban (Aug. 18, 2017)
    31. Exhibit 71 - Dept of Health & Human Servs., Departmental Appeals Bd., Appellate Div., Decision No. 2576 (May 30, 2014)
    32. Exhibit 72 - OASH, Gender-Affirming Care and Young People
    33. Exhibit 73 - SAMHSA, Ending Conversion Therapy (Oct. 2015)
    34. Exhibit 74 - SAMHSA, Moving Beyond Change Efforts (2023)
    35. Exhibit 75 - NCTSN, Gender-Affirming Care is Trauma-Informed Care
    36. Exhibit 76 - U.S. Presidential Proclamation, Transgender Day of Visibility, 2022
    37. Exhibit 77 - U.S. Presidential Proclamation, Transgender Day of Visibility, 2023
    38. Exhibit 78 - Executive Order, Preventing and Combating Discrimination on the Basis of Gender Identity or Sexual Orientation (Jan. 20, 2021)
    39. Exhibit 79 - Medicaid Coverage for Gender-Affirming Care, Williams Institute (Dec. 2022)
    40. Exhibit 80 - Excerpts from trial transcript Vol. 5 (Levine), Brandt v. Rutledge, 4:21-CV-00450-JM (E.D. Ark.)
  • Mentions or contains: deposition: Exhibit List (Notice of Filing, Part 4 of 10) Open(opens another site) · In the case's documents
    40 attachments
    1. Exhibit 121 - On Gender Dysphoria, 2017 Dhejne
    2. Exhibit 122 - Long-Term Follow-up of Transsexual Persons Undergoing Sex Reassignment Surgery, 2011 Dhejne
    3. Exhibit 123 - Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons, 2017 Hembree et al.
    4. Exhibit 124 - Interrogating Gender-Exploratory Therapy, 2023 Ashley
    5. Exhibit 125 - Transgender Surgery & Christian Anthropology, Presentation by Patrick W. Lappert
    6. Exhibit 126 - What is Psychiatry, American Psychiatric Association
    7. Exhibit 127 - Lewiss Child and Adolescent Psychiatry, Fifth Edition, 2018
    8. Exhibit 128 - Memo Outlining Evidence for Change for Gender Identity Disorder in the DSM-5, 2013 Zucker, et al.
    9. Exhibit 129 - A Developmental, Biopsychosocial Model for the Treatment of Children with Gender Identity Disorder, 2012 Zucker
    10. Exhibit 130 - APA Statement on Zucker (2008)
    11. Exhibit 131 - Working for Inclusion: Time for Congress to Enact Federal Legislation to Address Workplace Discrimination Against Lesbian, Gay, Bisexual, and Transgender Americans, Briefing Report
    12. Exhibit 132 - Position Statement on Conversion Therapy, APA (Dec. 2018)
    13. Exhibit 133 - Do Clinical Data from Transgender Adolescents Support the Phenomenon of Rapid Onset Gender Dysphoria, 2022 Bauer et al.
    14. Exhibit 134 - American Society of Plastic Surgeons, State Focus on Gender Affirmation Intensifies, Feb. 25, 2021,
    15. Exhibit 135 - Plastic surgeon: Sex-change operation utterly unacceptable and a form of child abuse, Sept. 9, 2019,
    16. Exhibit 136 - Transphobic tweets linked to Oxford sociology professor, The Oxford Student (Oct. 26, 2018)
    17. Exhibit 137 - Long-term outcomes of the treatment of central precocious puberty, 2016 Guaraldi, et al.
    18. Exhibit 138 - Fertility of Women Treated during Childhood with Triptorelin (Depot Formulation) for Central Precocious Puberty, 2021 Martinerie, et al.
    19. Exhibit 139 - Gender dysphoria in childhood, 2016 Ristori & Steensman
    20. Exhibit 140 - Gender Identity 5 Years After Social Transition, 2022 Olson et al.
    21. Exhibit 141 - Puberty Suppression in Adolescents With Gender Identity Disorder, 2011 de Vries, et al.
    22. Exhibit 142 - Understanding the Well-Being of LGBTQI+ Populations, 2020 Natl Academies of Sciences, Engineering, and Medicine
    23. Exhibit 143 - The Health of Lesbian, Gay, Bisexual and Transgender People, 2011 Natl Academies of Sciences, Engineering, and Medicine
    24. Exhibit 144 - The Right to the Best Care for Children Does Not Include the Right to Medical Transition, 2019 Laidlaw, et al.
    25. Exhibit 145 - Strangers in a Strange Land, 2020 Donovan & Sotomayor
    26. Exhibit 146 - Effect of antidepressant medications on semen parameters and male fertility, 2020 Beeder & Samplaski
    27. Exhibit 147 - The effect of antidepressants on fertility, 2016 Casilla-Lennon, et al.
    28. Exhibit 148 - Trends in Gender-affirming Surgery in Insured Patients in the U.S., 2018 Lane et al.
    29. Exhibit 149 - Gender-Affirming Treatment of Gender Dysphoria in Youth, 2022 Clayton et al.
    30. Exhibit 150 - AAP News, Risk of Pseudotumor Cerebri added to Labeling for Gonadotropin-Releasing Hormone Agonists, (2022)
    31. Exhibit 151 - Longitudinal Impact of Gender-Affirming Endocrine Intervention on the Mental Health and Well-Being of Transgender Youths, 2020 Achille et al.
    32. Exhibit 152 - Long-Term Effect of Gender-Affirming Hormone Treatment on Depression and Anxiety Symptoms in Transgender People, 2020 Aldridge et al.
    33. Exhibit 153 - Off-Label Medication use in Children, More Common than We Think: A Systematic Review of the Literature, 2018 Allen et al.
    34. Exhibit 154 - Association Between Gender-Affirming Surgeries and Mental Health Outcomes, 2021 Almazan et al.
    35. Exhibit 155 - Top Surgery and Chest Dysphoria Among Transmasculine and Nonbinary Adolescents and Young Adults, 2022 Ascha et al.
    36. Exhibit 156 - Hormone Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review, 2021 Baker et al.
    37. Exhibit 157 - GRADE Guidelines: 3 Rating the Quality of Evidence, 2011 Balshem et al.
    38. Exhibit 158 - Harry Benjamin, The Transsexual Phenomenon (1966)
    39. Exhibit 159 - Anabolic Steroid Abuse and Dependence, 2002 Brower et al.
    40. Exhibit 160 - Transgender and Gender-Nonbinary Patient Satisfaction after Transmasculine Chest Surgery, 2021 Bustos et al.
  • Mentions or contains: deposition: Exhibit List (Notice of Filing, Part 5 of 10) Open(opens another site) · In the case's documents
    40 attachments
    1. Exhibit 161 - Regret after Gender-affirmation Surgery: A Systematic Review and Metaanalysis of Prevalence, 2021 Bustos et al.
    2. Exhibit 162 - Effects of Long-Term Exogenous Testosterone Administration on Ovarian Morphology, Determined by Transvaginal (3D) Ultrasound in Female-to-Male Transsexuals, 2017 Caanen et al.
    3. Exhibit 163 - Short-term Outcomes of Pubertal Suppression in a Selected Cohort of 12 to 15 Year Old Young People with Persistent Gender Dysphoria in the UK, 2021 Carmichael at al.
    4. Exhibit 164 - Psychosocial Functioning in Transgender Youth after 2 Years of Hormones, 2023 Chen et al.
    5. Exhibit 165 - Pubertal Delay as an Aid in Diagnosis and Treatment of a Transsexual Adolescent, 1998 Cohen-Kettenis & van Goozen
    6. Exhibit 166 - Hormonal Treatment Reduces Psychobiological Distress in Gender Identity Disorder, Independently of the Attachment Style, 2013 Colizzi et al.
    7. Exhibit 167 - Psychological Support, Puberty Suppression, and Psychosocial Functioning in Adolescents with Gender Dysphoria, 2015 Costa et al.
    8. Exhibit 168 - Young Adult Psychological Outcome After Puberty Suppression and Gender Reassignment, 2014 de Vries et al.
    9. Exhibit 169 - An Analysis of All Applications for Sex Reassignment Surgery in Sweden, 1960-2010: Prevalence, Incidence, and Regrets, 2014 Dhejne et al.
    10. Exhibit 170 - Gender Nonconforming Youth: Current Perspectives, 2017 Ehrensaft
    11. Exhibit 171 - What makes clinical research ethical?, 2000 Emanuel et al.
    12. Exhibit 172 - Treatment of Central Precocious Puberty, 2019 Eugster
    13. Exhibit 173 - Cross-Sex Hormone Treatment and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data, 2016 Fisher et al.
    14. Exhibit 174 - Chest Surgery in Female to Male Transgender Individuals, 2017 Frederick et al.
    15. Exhibit 175 - Off-Label Use of Drugs in Children, 2014 Galinkin et al.
    16. Exhibit 176 - Association of Gender-Affirming Hormone Therapy With Depression, Thoughts of Suicide, and Attempted Suicide Among Transgender and Nonbinary Youth, 2022 Green
    17. Exhibit 177 - Feminizing Genital Gender-Confirmation Surgery, 2018 Hadj-Moussa et al.
    18. Exhibit 178 - Satisfaction with Male-to-Female Gender Reassignment Surgery, 2014 Hess et al.
    19. Exhibit 179 - Effects of Different Steps in Gender Reassignment Therapy on Psychopathology, 2014 Heylens, et al.
    20. Exhibit 180 - Supporting Sexuality and Improving Sexual Function in Transgender Persons, 2019 Holmberg et al.
    21. Exhibit 181 - Outcome of Vaginoplasty in Male-to-Female Transgenders: A Systematic Review of Surgical Techniques, 2015 Horbach et al.
    22. Exhibit 182 - The Quality of Evidence for Medical Interventions Does Not Improve or Worsen: A Metaepidemiological Study of Cochrane Reviews, 2020 Howick et al.
    23. Exhibit 183 - Testosterone Treatment and MMPI2 Improvement in Transgender Men, 2015 Keo-Meier et al.
    24. Exhibit 184 - Bone Mass in Young Adulthood Following Gonadotropin-Releasing Hormone Analog Treatment and Cross-Sex Hormone Treatment in Adolescents with Gender Dysphoria, 2015 Klink et al.
    25. Exhibit 185 - Fertility Options in Transgender and Gender Diverse Adolescents, 2017 Knudson & De Sutter
    26. Exhibit 186 - Australian Children and Adolescents with Gender Dysphoria, 2021 Kozlowska et al.
    27. Exhibit 187 - Body Dissatisfaction and Mental Health Outcomes of Youth on Gender-Affirming Hormone Therapy, 2020 Kuper et al.
    28. Exhibit 188 - Transgender Men Who Experienced Pregnancy After Female-to-Male Gender Transitioning, 2014 Light, et al.
    29. Exhibit 189 - Psychosocial Assessment in Transgender Adolescents, 2020 Lopez de Lara.
    30. Exhibit 190 - Christy Mallory et al., Conversion Therapy and LGBT Youth 2 (2019 ed.)
    31. Exhibit 191 - Successful Oocyte Cryopreservation Using Letrozole as an Adjunct to Stimulation in a Transgender Adolescent after GnRH Agonist Suppression, 2021 Martin et al.
    32. Exhibit 192 - Experience of Chest Dysphoria and Masculinizing Chest Surgery in Transmasculine Youth, 2021 Mehringer et al.
    33. Exhibit 193 - Breast Augmentation in Male-to-Female Transgender Patients: Technical Considerations and Outcomes, 2019 Miller et al.
    34. Exhibit 194 - Guiding the ConversationTypes of Regret after Gender-Affirming Surgery and Their Associated Etiologies, 2021 Narayan et al.
    35. Exhibit 195 - Individual Treatment Progress Predicts Satisfaction with Transition-Related Care for Youth with Gender Dysphoria, 2021 Nieder et al.
    36. Exhibit 196 - Sexual Experiences in Transgender People, 2018 Nikkelen & Baudewijntje.
    37. Exhibit 197 - Quality of Life of Treatment-Seeking Transgender Adults, 2018 Nobili et al.
    38. Exhibit 198 - Chest Reconstruction and Chest Dysphoria in Transmasculine Minors and Young Adults: Comparisons of Nonsurgical and Postsurgical Cohorts, 2018 Olson-Kennedy et al.
    39. Exhibit 199 - Mental Health of Transgender Children Who Are Supported in Their Identities, 2016 Olson, et al.
    40. Exhibit 200 - Association Between Gender Confirmation Treatments and Perceived Gender Congruence, Body Image Satisfaction, and Mental Health in a Cohort of Transgender Individuals, 2018 Owen-Smith, et al.
  • Mentions or contains: deposition: Exhibit List (Notice of Filing, Part 7 of 10) Open(opens another site) · In the case's documents
    40 attachments
    1. Exhibit 237A - (Placeholder) Dekker medical records
    2. Exhibit 238 - GAPMS Decision Tree Checklist
    3. Exhibit 239 - GAPMS GnRH for treatment of gender dysphoria
    4. Exhibit 240 - GAPMS GnRH for treatment of gender dysphoria
    5. Exhibit 241 - GAPMS Cross Sex Hormone Therapy 5/20/2022
    6. Exhibit 242 - GAPMS Cross Sex Hormone Therapy Report (edited) - 5/20/2022
    7. Exhibit 243 - GAPMS Cross Sex Hormone Therapy 11/2/2016
    8. Exhibit 244 - GAPMS Gender Confirmation Surgery (incomplete) 7/19/2017
    9. Exhibit 245 - DUR Meeting Transcript 9/26/2015
    10. Exhibit 246 - DUR Quarterly Report - 2015
    11. Exhibit 247 - DUR Meeting Minutes 1/16/2016
    12. Exhibit 248 - DUR Meeting Minutes 9/24/2016
    13. Exhibit 249 - Pharmacy log 5/31/2016
    14. Exhibit 250 - AHCA review of research 7/25/2016
    15. Exhibit 251 - AHCA review of state practice 8/17/2016
    16. Exhibit 252 - Arlene Elliot research regarding Medicaid coverage of care in other states July 27, 2016
    17. Exhibit 252A - Arlene Elliot research regarding Medicaid coverage of care in other states July 27, 2016
    18. Exhibit 252B - Arlene Elliot research regarding Medicaid coverage of care in other states July 27, 2016
    19. Exhibit 252C - Arlene Elliot research regarding Medicaid coverage of care in other states July 27, 2016
    20. Exhibit 253 - Aetna clinical criteria for cross-sex hormone therapy 8/18/2016
    21. Exhibit 254 - Arlene Elliot email re GnRH coverage 8/29/2016
    22. Exhibit 255 - Rebecca Borgert email regarding Endocrine Society guidelines 8/29/2016
    23. Exhibit 256 - AHCA GAPMS routing and tracking form for puberty suppression therapy 8/31/2016
    24. Exhibit 257 - Special services criteria re GnRH coverage 9/20/2016 (updated 11/17/17)
    25. Exhibit 258 - AHCA letter to Childrens Medical Services re drug criteria and coverage 10/6/2016
    26. Exhibit 259 - AHCA tracking form for GAPMS research re puberty suppression 9/26/2016
    27. Exhibit 260 - AHCA GAPMS routing and tracking form for cross-sex hormone therapy 11/2/2016
    28. Exhibit 261 - FL House letter to AHCA re drug treatment for gender dysphoria 11/22/2016
    29. Exhibit 262 - DUR transcript 3/23/2017
    30. Exhibit 263 - Draft GAPMS re gender-affirming surgery 7/19/2017
    31. Exhibit 264 - Email exchange re Medicaid coverage of gender affirming surgery June 2018
    32. Exhibit 264A - Email exchange re Medicaid coverage of gender affirming surgery June 2018
    33. Exhibit 265 - AHCA routing form tracking response to MCO question about Medicaid coverage of surgery June 2018
    34. Exhibit 266 - AHCA document closing the project re responding to MCO question about Medicaid coverage of surgery June 2018
    35. Exhibit 267 - Email from Theresa Kumar to Jesse Botcher 10/18/2019
    36. Exhibit 268 - Email from DD Pickle to Krisin Sokoloski 1/5/2022
    37. Exhibit 269 - AHCA approval of Simply Healthcares provider manual 3/24/2022
    38. Exhibit 269A - AHCA approval of Simply Healthcares provider manual 3/24/2022
    39. Exhibit 269B - AHCA approval of Simply Healthcares provider manual 3/24/2022
    40. Exhibit 269C - AHCA approval of Simply Healthcares provider manual 3/24/2022
  • Mentions or contains: deposition: Exhibit List (Notice of Filing, Part 8 of 10) Open(opens another site) · In the case's documents
    40 attachments
    1. Exhibit 270 - Email re commercial plan coverage 3/24/2022
    2. Exhibit 271 - Communication from Peter Ring re procedures billed to treat gender dysphoria 4/7/2022
    3. Exhibit 272 - Email from Andy Bardos to Andrew Sheeran re Cantor and legal research 4/11/2022
    4. Exhibit 273 - Email forwarded by Andrew Sheeran from Ashley Lukis scheduling a call with James Cantor 4/13/2022
    5. Exhibit 274 - Email from Andrew Sheeran to Miriam Grossman 4/14/2022
    6. Exhibit 275 - Email exchange between Andrew Sheeran and Romina Brignardello Petersen 4/18/2022
    7. Exhibit 276 - Email from Susan Williams to Shantrice Green re GAPMS on cross-sex hormone therapy 4/20/2022
    8. Exhibit 277 - Email from Amy Zitiello to Vern Hamilton regarding FDOH guidance 4/20/2022
    9. Exhibit 277A - Email from Amy Zitiello to Vern Hamilton regarding FDOH guidance 4/20/2022
    10. Exhibit 278 - Email from Cody Farill regarding data from Magellan about drug coverage - 4/20/2022
    11. Exhibit 279 - Communication between Jason Weida and Dr. Michelle Cretella 4/21/2025
    12. Exhibit 280 - Communication between Romina Brignardello-Petersen and Jason Weida regarding types of surgeries on which to focus 4/25/2022
    13. Exhibit 281 - Communication between Jason Weida and Vern Hamilton regarding planned response to Dr. Zitiellos question about FDOH guidance 4/29/2022
    14. Exhibit 282 - Draft GAPMS on gender affirming surgery (with handwritten notes) - May 2022
    15. Exhibit 283 - Jason Weida communication regarding report from Romina Brignardello-Petersen 5/5/2022
    16. Exhibit 283A - Jason Weida communication regarding report from Romina Brignardello-Petersen 5/5/2022
    17. Exhibit 283B - Jason Weida communication regarding report from Romina Brignardello-Petersen 5/5/2022
    18. Exhibit 283C - Jason Weida communication regarding report from Romina Brignardello-Petersen 5/5/2022
    19. Exhibit 283D - Jason Weida communication regarding report from Romina Brignardello-Petersen 5/5/2022
    20. Exhibit 283E - Jason Weida communication regarding report from Romina Brignardello-Petersen 5/5/2022
    21. Exhibit 284 - Jason Weida communication regarding articles provided to him by Dr. Van Mol 5/6/2022
    22. Exhibit 285 - Dr. Van Mol communication with Jason Weida and Matthew Brackett about gender affirming care 5/7/022
    23. Exhibit 286 - Dr. Van Mols edits to June 2022 GAPMS memo 5/13/2022
    24. Exhibit 286A - Dr. Van Mols edits to June 2022 GAPMS memo 5/13/2022
    25. Exhibit 286B - Dr. Van Mols edits to June 2022 GAPMS memo 5/13/2022
    26. Exhibit 287 - Text message from Jason Weida regarding Eknes-Tucker and James Cantor 5/17/2022
    27. Exhibit 288 - Email from Shantrice Green to Susan Williams and Kelly Rubin regarding the GAPMS memo on cross-sex hormone therapy 5/20/2022
    28. Exhibit 289 - Draft of GAPMS cross-sex hormone therapy memo 5/20/2022
    29. Exhibit 290 - Jason Weida asks Dr. Van Mol for assistance locating specific witnesses 5/21/2022
    30. Exhibit 291 - Email between Dr. Van Mol and Jason Weida regarding reimbursement 5/21/2022
    31. Exhibit 292 - Invoices from Romina Brignardello-Petersen 5/24/2022
    32. Exhibit 292A - Invoices from Romina Brignardello-Petersen 5/24/2022
    33. Exhibit 293 - Template denial for requesting rule workshop June 2022
    34. Exhibit 294 - Projected Rulemaking Timeline June 2022
    35. Exhibit 295 - Gender Dysphoria/Transgender Health Care Non-Legislative Pathway June 2022
    36. Exhibit 296 - Gender Dysphoria/Transgender Health Care Policy Pathway June 2022
    37. Exhibit 297 - AHCA GAPMS routing and tracking form for June 2022 GAPMS 6/1/2022
    38. Exhibit 297A - AHCA GAPMS routing and tracking form for June 2022 GAPMS 6/1/2022
    39. Exhibit 298 - Communication between Ashley Peterson and Jason Weida regarding an inventory of gender affirming care 6/3/2022
    40. Exhibit 298A - Communication between Ashley Peterson and Jason Weida regarding an inventory of gender affirming care 6/3/2022
  • Mentions or contains: deposition: Exhibit List (Notice of Filing, Part 9 of 10) Open(opens another site) · In the case's documents
    40 attachments
    1. Exhibit 299 - (Redacted) Email communication between AHCA and Magellan regarding coverage of GnRH to treat gender dysphoria
    2. Exhibit 300 - AHCA communication regarding the Special Services Criteria for puberty blockers 6/10/2022
    3. Exhibit 301 - Communication between Jason Weida and Dr. Van Mol about a witness for the July 8th hearing 6/14/2022
    4. Exhibit 302 - Email communication between Dr. Christopher Cogle and Jeffrey English 6/27/2022
    5. Exhibit 303 - Communication regarding meeting between Miriam Grossman, Dr. Van Mol, Jason Weida, Andrew Sheeran, and Holtzman Vogel regarding July 8th hearing 6/30/2022
    6. Exhibit 304 - Communication between Dr. Van Mol and AHCA - 7/2/2022
    7. Exhibit 305 - Brief of the July 8th rule hearing 7/8/2022
    8. Exhibit 306 - Transcript from July 8th rule hearing 7/8/2022
    9. Exhibit 307 - Email from Miriam Grossman 7/10/2022
    10. Exhibit 308 - Email communications with Jason Weida and Dr. Van Mol 7/14/2022
    11. Exhibit 309 - Communications regarding AHCAs development of public comment binder provided to the consultants 7/19/2022
    12. Exhibit 310 - Invoice from Dr. Van Meter 8/4/2022
    13. Exhibit 311 - Communication to Jason Weida regarding witnesses for a hearing 8/10/2022
    14. Exhibit 312 - Invoices from Dr. Van Mol 8/11/2022
    15. Exhibit 313 - Email communications regarding implementation of 59G-1.050(7) - 8/22/2022
    16. Exhibit 313A - Email communications regarding implementation of 59G-1.050(7) - 8/22/2022
    17. Exhibit 314 - Communication between AHCA and EOG regarding planned communications about June 2022 GAPMS and 59G-1.050(7) - 8/22/2022
    18. Exhibit 315 - SMMC Policy Transmittal draft regarding non-coverage of gender dysphoria treatments August 22, 2022
    19. Exhibit 316 - AHCA Medicaid Health Care Alert regarding prohibition on coverage for gender affirming care
    20. Exhibit 317 - AHCA draft response to media regarding gender affirming care 9/1/2022
    21. Exhibit 318 - List of appeals for denials of hormone therapy 12/19/2022
    22. Exhibit 319 - List of requests for surgery to treat gender dysphoria 12/19/2022
    23. Exhibit 320 - AHCA After the Fact Request form for Quentin Van Meter 6/13/2022
    24. Exhibit 321 - AHCA After the Fact Request form for Andre Van Mol 5/26/2022
    25. Exhibit 322 - Draft of welcome/opening remarks for July 8th rule hearing
    26. Exhibit 323 - Endocrine Society public comment
    27. Exhibit 324 - Yale public comment
    28. Exhibit 325 - American Academy of Pediatrics public comment
    29. Exhibit 326 - Florida Medicaid, Comment Summary for Rule 59G-1.050 (20 pages)
    30. Exhibit 327 - Florida Medicaid, Comment Summary for Rule 59G-1.050 (17 pages)
    31. Exhibit 328 - Email communication between Van Mol and Weida and attachment
    32. Exhibit 328A - Email communication between Van Mol and Weida and attachment
    33. Exhibit 329 - Florida Medicaid & G/TAT, Andrea Van Mol May 2022
    34. Exhibit 330 - GAPMS Specially Modified Foods
    35. Exhibit 331 - GAPMS Scleral Contact Lenses
    36. Exhibit 332 - GAPMS Fractional Exhaled Nitric Oxide
    37. Exhibit 333 - GAPMS Breast Pump
    38. Exhibit 334 - Email from Miriam Grossman July 7, 2022
    39. Exhibit 335 - Proposed media response from Brock Juarez to Taryn Fenske 8/29/2022
    40. Exhibit 336 - Order striking Van Meter
  • Mentions or contains: deposition: Exhibit List (Notice of Filing, Part 10 of 10) Open(opens another site) · In the case's documents
    21 attachments
    1. Exhibit 337 - Email communication between Van Meter and AHCA Counsel
    2. Exhibit 338 - AHCA Microsoft Teams Meeting Invite
    3. Exhibit 339 - Email communication between Van Meter and Jason Weida
    4. Exhibit 340 - AHCA Van Meter Invoice
    5. Exhibit 341 - HCA Hearing on General Medicaid Policy
    6. Exhibit 342 - Email communication between Devona Pickle and Van Meter
    7. Exhibit 343 - Email communication between consultants, counsel, and Van Meter
    8. Exhibit 344 - AHCA Teams Meeting Invites
    9. Exhibit 344A - AHCA Teams Meeting Invites
    10. Exhibit 345 - Email communication between AHCA and consultants
    11. Exhibit 346 - Email communication between Sheeran and Brignardello-Petersen
    12. Exhibit 347 - Email communication between Van Mol and Weida
    13. Exhibit 348 - Van Mol comments to Alstott letter
    14. Exhibit 349 - Email communication between Weida Van Meter, Van Mol and Grossman
    15. Exhibit 350 - Email communication between Cantor and Weida
    16. Exhibit 351 - Sex Differences in Verbal Fluency during Adolescence, 2013 Soleman
    17. Exhibit 352 - Oestrogens are Not Related to Emotional Processing, Soleman 2016
    18. Exhibit 353 - Puberty suppression and executive functioning, 2015 Staphorsius
    19. Exhibit 354 - Alterations in the inferior fronto-occipital fasciculus, van Heesewijk
    20. Exhibit 355 - Spreadsheet summarizing Florida Medicaid coverage
    21. Exhibit 356 - DOJ, Dear State Attorneys General Letter re Transgender Youth (March 31, 2022)
  • Mentions or contains: declaration: PRETRIAL Stipulation Open(opens another site) · In the case's documents
  • Mentions or contains: declaration: Appendix 3 - Plaintiffs' Amended Exhibit List Open(opens another site) · In the case's documents

Doe v. Ladapo N.D. Fla. · 2024

Maxwell Kadel v. Dale Folwell 4th Cir. · 2022

3 more documents

Paul Eknes-Tucker v. Governor of the State of Alabama 11th Cir. · 2022

7 more documents

How courts have treated their testimony

Each ruling that discusses their testimony, by what it did for the side that called them. The counts are the profile's own, for the rulings it lists.

Discounted, criticized or limited: 5Neither: 2
Helped the side that called them: 0Credited against the side that called them: 0Discounted, criticized or limited: 5Neither: 2
2023

Dekker v. Weida

Discounted, criticized or limitedCriticized

U.S. District Court, N.D. Florida · trial / merits (order following bench trial) · court order

Their role: retained by defendants (state Medicaid agency) to testify at trial

After a bench trial, Judge Hinkle found that Dr. Hruz 'fended and parried questions and generally testified as a deeply biased advocate, not as an expert sharing relevant evidence-based information and opinions,' and stated he did not credit Hruz's testimony at all (crediting other defense experts only insofar as consistent with the court's own findings). The court separately noted Hruz had joined an amicus brief in another proceeding describing transgender identity as a 'false belief.'

“one of the defendants’ experts, Dr. Paul Hruz, joined an amicus brief in another proceeding asserting transgender individuals have only a “false belief” in their gender identity”

Dekker v. Weida: Order

“Dr. Hruz fended and parried questions and generally testified as a deeply biased advocate, not as an expert sharing relevant evidence-based information and opinions. I do not credit his testimony.”

Dekker v. Weida: Order

Source: Dekker v. Weida: Order

2023

Doe v. Ladapo

Discounted, criticized or limitedCriticized

U.S. District Court, N.D. Florida · preliminary injunction · court order

Their role: defendants' expert in the related Dekker v. Weida trial; not shown to have testified in Doe v. Ladapo itself

In granting a preliminary injunction in a separate but related Florida case, Judge Hinkle repeated, essentially verbatim, his assessment from the Dekker v. Weida trial record that Dr. Hruz 'fended and parried questions and generally testified as a deeply biased advocate' and that the court did not credit his testimony, again referencing Hruz's amicus-brief statements describing transgender identity as a 'false belief.' The citations are to the Dekker trial transcript, not to testimony given in this case.

“Dr. Hruz fended and parried questions and generally testified as a deeply biased advocate, not as an expert sharing relevant evidence-based information and opinions. I do not credit his testimony.”

DOE v. LADAPO: Order on Motion for Preliminary Injunction

Source: DOE v. LADAPO: Order on Motion for Preliminary Injunction

2023

Dylan Brandt v. Tim Griffin

Discounted, criticized or limitedCriticized

U.S. District Court, Eastern District of Arkansas · trial - Findings of Fact and Conclusions of Law (post-trial, permanent injunction) · court order

Their role: retained by the state (defendant) to testify at trial as a pediatric endocrinologist

Following trial, the court found Dr. Hruz had never treated a patient for gender dysphoria and declined to credit his opinion that the body of research supporting gender-affirming care is unreliable or that such care is not effective, finding decades of clinical experience and research demonstrate its effectiveness. The court found Hruz, along with two other state experts recruited at the same advocacy-group seminar, 'unqualified to offer relevant expert testimony' and testifying 'more from a religious doctrinal standpoint' than as Daubert-qualified experts, with opinions 'grounded in ideology rather than science,' citing similar assessments in Doe v. Ladapo and Kadel v. Folwell.

“Dr. Hruz has never treated a patient for gender dysphoria.”

Dylan Brandt v. Tim Griffin: Originating court document filed consisting of notice of appeal, Findings of Fac

“The Court does not credit these opinions because it finds that the evidence showed that decades of clinical experience in addition to a body of scientific research demonstrate the effectiveness of these treatments.”

Dylan Brandt v. Tim Griffin: Originating court document filed consisting of notice of appeal, Findings of Fac

“it does not credit Dr. Hruz’s assessment that the entire body of research is, therefore, meaningless.”

Dylan Brandt v. Tim Griffin: Originating court document filed consisting of notice of appeal, Findings of Fac

“it is clear from listening to the testimony that Professor Mark Regnerus, Dr. Paul Hruz, and Dr. Lappert were testifying more from a religious doctrinal standpoint rather than that required of experts by Daubert.”

Dylan Brandt v. Tim Griffin: Originating court document filed consisting of notice of appeal, Findings of Fac

“Most of the State’s expert witnesses, Professor Mark Regnerus, Dr. Stephen Lappert, and Dr. Paul Hruz, were unqualified to offer relevant expert testimony and offered unreliable testimony. Their opinions regarding gender-affirming medical care for adolescents with gender dysphoria are grounded in ideology rather than science.”

Dylan Brandt v. Tim Griffin: Originating court document filed consisting of notice of appeal, Findings of Fac

Source: Dylan Brandt v. Tim Griffin: Originating court document filed consisting of notice of appeal, Findings of Fac

2023

L.W. v. Skrmetti

Discounted, criticized or limitedGiven little weight

U.S. District Court, Middle District of Tennessee · preliminary injunction · court order

Their role: retained by the state (defendant) to testify regarding gender-affirming care for minors

Ruling on a preliminary-injunction motion, the district court found the testimony of Dr. Cantor and Dr. Hruz 'minimally persuasive' because neither had ever diagnosed or treated a minor with gender dysphoria, consistent with other courts' treatment of Hruz (citing the Kadel district court's qualification limits and Judge Hinkle's Doe v. Ladapo comments). The court expressly declined to find Hruz a 'deeply biased advocate' as Judge Hinkle had, but still discounted his testimony for lack of direct clinical experience diagnosing or treating gender dysphoria.

“the Court agrees with Plaintiffs that the testimony of Dr. Cantor and Dr. Hruz is minimally persuasive”

L. W. v. Jonathan Skrmetti: MEMORANDUM OPINION

“Judge Hinkle commented that Dr. Hruz’s testimony was that of a “deeply biased advocate, not [] an expert sharing relevant evidence-based information and opinions,””

L. W. v. Jonathan Skrmetti: MEMORANDUM OPINION

“The undersigned sees no current need or basis to accuse Dr. Hruz of being a deeply biased advocate posing as an expert, but he does discern the need to discount Dr. Hruz’s testimony somewhat for the reasons mentioned.”

L. W. v. Jonathan Skrmetti: MEMORANDUM OPINION

Source: L. W. v. Jonathan Skrmetti: MEMORANDUM OPINION

2024

Maxwell Kadel v. Dale Folwell (consolidated with Shauntae Anderson v. William Crouch)

Discounted, criticized or limitedLimited

U.S. Court of Appeals for the Fourth Circuit (en banc) · appeal - Rule 702 (Daubert-type) evidentiary ruling reviewed for abuse of discretion · court opinion

Their role: retained by North Carolina (defendant) to testify about the treatment of gender dysphoria

The en banc Fourth Circuit affirmed the district court's decision to limit Dr. Hruz's expert testimony: he was not permitted to testify about the diagnosis of gender dysphoria, the DSM, its potential causes, desistance rates, or the efficacy of mental-health treatments (he is not a psychiatrist, psychologist, or mental-health professional and had not researched, diagnosed, or treated gender dysphoria), but the district court still allowed him to testify to the risks of puberty-blocking medication and hormone therapy based on his career treating patients and academic research on hormone effects. The court of appeals found no abuse of discretion in that partial exclusion.

“Dr. Hruz was not qualified to testify about “the diagnosis of gender dysphoria, the DSM, gender dysphoria’s potential causes, the likelihood that a patient will ‘desist,’ or the efficacy of mental health treatments.””

Shauntae Anderson v. William Crouch: Published authored opinion filed

“the district court still allowed Dr. Hruz “to testify to the risks associated with puberty blocking medication and hormone therapy,” based on his “long career treating patients and conducting academic research on the effects of hormone treatments.””

Shauntae Anderson v. William Crouch: Published authored opinion filed

Source: Shauntae Anderson v. William Crouch: Published authored opinion filed

2024

Maxwell Kadel v. Dale Folwell (consolidated with Shauntae Anderson v. William Crouch)

NeitherCited in a separate opinion

U.S. Court of Appeals for the Fourth Circuit (en banc) · appeal - Rule 702 (Daubert-type) evidentiary ruling, dissent · court opinion

Their role: retained by North Carolina (defendant) to testify about the treatment of gender dysphoria

Dissenting, Judge Quattlebaum argued the majority misapplied Rule 702 by affirming the exclusion of Dr. Hruz's gender-dysphoria testimony. Reviewing Hruz's clinical background (a pediatric endocrinologist who has treated hundreds of juveniles with sexual-development disorders and transgender patients experiencing hormone-treatment side effects, studied the literature, and presented at medical centers), Quattlebaum concluded Hruz had the requisite 'knowledge' to qualify as an expert on gender dysphoria under Rule 702's disjunctive test, and that the district court abused its discretion in excluding his testimony; he would have treated any gaps in Hruz's direct clinical experience as going to weight, not admissibility. This is a dissenting view, not the court's holding.

“the majority misapplies Federal Rule of Evidence 702 by affirming the exclusion of Dr. Paul W. Hruz’s gender dysphoria testimony.”

Shauntae Anderson v. William Crouch: Published authored opinion filed

“As a pediatric endocrinologist, Dr. Hruz has “participated in the care of hundreds of infants and children, including adolescents,”

Maxwell Kadel v. Dale Folwell, 2024(opens another site)

“Dr. Hruz is an endocrinologist who has treated hundreds of juveniles diagnosed with sexual development disorders”

Maxwell Kadel v. Dale Folwell, 2024(opens another site)

“Dr. Hruz, therefore, has the necessary knowledge to qualify him to testify on the subject of gender dysphoria.”

Shauntae Anderson v. William Crouch: Published authored opinion filed

“district court abused its discretion in excluding Dr. Hruz’s testimony about gender dysphoria.”

Shauntae Anderson v. William Crouch: Published authored opinion filed

“concerns of his lack of experience in diagnosing, treating or researching gender dysphoria went to the weight of his proffered testimony, not its admissibility.”

Shauntae Anderson v. William Crouch: Published authored opinion filed

Source: Shauntae Anderson v. William Crouch: Published authored opinion filed

2024

Maxwell Kadel v. Dale Folwell (consolidated with Shauntae Anderson v. William Crouch)

NeitherDescribed, not weighedmedium confidence

U.S. Court of Appeals for the Fourth Circuit (en banc) · appeal - equal protection analysis, dissent · court opinion

Their role: author of a declaration cited as record evidence of medical debate (not independently assessed for credibility in this passage)

In the equal-protection portion of his dissent, Judge Richardson cited Dr. Hruz's expert witness declaration (alongside Dr. Stephen Levine's disclosure report in the companion Anderson case) simply as record evidence that an 'ongoing debate' exists over the medical efficacy and necessity of gender-dysphoria treatments, supporting the states' cost-based, non-discriminatory rationale for the coverage exclusions. The passage does not assess Dr. Hruz's credibility or qualifications; it is also a dissent, not the court's holding.

“the evidence on record shows that there is an ongoing debate over this issue.”

Maxwell Kadel v. Dale Folwell, 2024(opens another site)

Source: Maxwell Kadel v. Dale Folwell, 2024(opens another site)

Not in the archive: The Kadel v. Folwell district court's underlying Daubert order (M.D.N.C., cited in these documents as Kadel, 620 F. Supp. 3d 339, 368 (M.D.N.C. 2022) and as 'Kadel, J.A. 3587') is referenced repeatedly by the Fourth Circuit majority and dissents but its full text is not among these files; the specific quoted qualification limits (e.g., that Hruz 'is not a psychiatrist, psychologist, or mental healthcare professional' and 'has never diagnosed a patient with gender dysphoria') are quoted secondhand by the court of appeals and by the L.W. v. Skrmetti order, not read directly from the district court's own opinion. Doe v. Ladapo, 2023 WL 3833848 (N.D. Fla. June 6, 2023) is cited by both the L.W. v. Skrmetti order and the Brandt v. Griffin findings for its 'comments on expert testimony of Lappert and Hruz'; the order in this set is the corresponding preliminary-injunction order and does contain that language, so this reference is resolved within these files. Eknes-Tucker/Boe v. Marshall's own court order or opinion assessing Hruz's testimony (if any) is not in this set — only the plaintiffs' reply brief attacking his declaration is included.

Cases and roles

CaseYearsArenaRetained byWhat they filed
Boe v. Marshall
U.S. District Court, Middle District of Alabama, Northern Division
2022-2024youth care banDefendants (State of Alabama officials) Expert reportEXPERT REPORTEXPERT REPORTDepositionNotice (Other)Expert reportExhibit 5 - Hruz ReportExhibit Hruz Report
+3 moreExhibit Hruz Deposition TranscriptNotice (Other)Exhibit 5
Carcaño v. McCrory
U.S. District Court, Middle District of North Carolina (Case No. 1:16-cv-00236-TDS-JEP)
2016other (public-facilities/restroom access under North Carolina HB2)Defendants Exhibit F - Hruz Declaration
DOE v. LADAPO
U.S. District Court, Northern District of Florida (order reviewed carries Case No. 4:23-cv-00114-RH-MAF)
2023-2024youth care banDefendants, as characterized by the court; not established in his own words because the folder holds no report or declaration text of his own from this docket Response in Opposition to MotionResponse in Opposition to Motion
Dekker v. Weida
U.S. District Court, Northern District of Florida, Tallahassee Division (Case No. 4:22-cv-00325-RH-MAF)
2022-2023insurance-MedicaidDefendants Exhibit Ex 13 Dr. Hruz Expert ReportExhibit A - Hruz ReportExhibit B - Hruz Rebuttal ReportExhibit C - Deposition of Paul W HruzExhibit E - Videotaped Deposition of Paul W Hruz MD PhDExhibit F - Deposition of Paul W Hruz MD PhDMotion in LimineExhibit Expert Witness Declaration of Paul W Hruz MD PhD (text is his declarati…
Maxwell Kadel v. Dale Folwell
U.S. District Court, Middle District of North Carolina (Case No. 1:19-cv-272-LCB-LPA)
2021-2023insurance-Medicaid (North Carolina State Health Plan exclusion)Defendants JOINT APPENDIX by Dale Folwell and Dee JonesJOINT APPENDIX by Dale Folwell and Dee JonesJOINT APPENDIX Vol. 1JOINT APPENDIX Vol. 2JOINT APPENDIX Vol. 3JOINT APPENDIX Vol. 4JOINT APPENDIX Vol. 5JOINT APPENDIX Vol. 6
+1 moreJOINT APPENDIX Vol.
Paul Eknes-Tucker v. Governor of the State of Alabama
U.S. District Court, Middle District of Alabama, Northern Division (Case No. 2:22-cv-00184-LCB-SRW; caption evidence shows this is the same docket number as Boe v. Marshall)
2022youth care banDefendants (State of Alabama officials) Volume I of XIIIVolume II of XIIIVolume III of XIIIVolume IV of XIIIVolume V of XIIIVolume VI of XIIIVolume VII of XIIIVolume VIII of XIII
+5 moreVolume IX of XIIIVolume X of XIIIVolume XI of XIIIVolume XII of XIII (FILED UNDER SEAL)Volume XIII of XIII

Typical stance

Most childhood gender dysphoria resolves on its own

He argues that the large majority of children with gender dysphoria will desist -- come to identify with their natal sex -- by the end of puberty if not medically or socially transitioned, making early intervention unnecessary for most patients.

“it is well established that 80-95% of children with gender dysphoria will resolve by the end of puberty without direct intervention to affirm transgender identity”

Carcaño v. McCrory: Exhibit F - Hruz Declaration

“High rate of desistance/natural resolution of gender dysphoria in children is not disclosed”

Dekker v. Weida: Exhibit Ex 13 Dr. Hruz Expert Report

Seen in: Carcaño v. McCrory, Dekker v. Weida, Boe v. Marshall

Hormonal treatment causes irreversible physical harm

He states that puberty blockers followed by cross-sex hormones commonly cause sterility and other irreversible physical effects, and that these risks are understated to patients and families.

“It is generally accepted, even by advocates of transgender hormone therapy, that hormonal treatment results in sterility which in many cases is irreversible.”

Carcaño v. McCrory: Exhibit F - Hruz Declaration

Seen in: Carcaño v. McCrory, Dekker v. Weida, Boe v. Marshall

Treatments are unapproved, off-label experimentation

He argues that puberty blockers and cross-sex hormones are not FDA-approved for treating gender dysphoria in minors, and that prescribing them for this purpose amounts to using patients as unwitting subjects in an unproven experiment.

“Uncontrolled social experimentation including the forced acceptance of altered norms for distinguishing persons according to biological sex is a potentially harmful and unscientific approach to dealing with this serious condition.”

Carcaño v. McCrory: Exhibit F - Hruz Declaration

“Using experimental procedures on uninformed, vulnerable patients is”

Dekker v. Weida: Exhibit Ex 13 Dr. Hruz Expert Report

Seen in: Carcaño v. McCrory, Dekker v. Weida, Boe v. Marshall

Adolescents cannot give truly informed consent

He contends that the informed-consent process for gender-affirming care is deficient -- failing to disclose desistance rates and the weak evidence base -- and that adolescents lack the neurodevelopmental capacity to weigh irreversible, long-term consequences.

“This is particularly concerning given that children are likely incapable of making informed consent to castrating treatments.”

Carcaño v. McCrory: Exhibit F - Hruz Declaration

“• “Implications of very low-quality evidence that underlies the practice of pediatric gender transition are not explained”; and,”

Dekker v. Weida: Exhibit Ex 13 Dr. Hruz Expert Report

Seen in: Carcaño v. McCrory, Dekker v. Weida, Boe v. Marshall

Adolescent brain development undermines capacity to consent

He points to ongoing structural and functional brain development in adolescence as a reason to doubt both the fixedness of a minor's stated gender identity and their capacity to make decisions about irreversible treatment.

“The limited emerging data has suggested structural and functional differences between brains from normal and transgender individuals. These data do not establish whether these differences are innate and fixed or acquired and malleable.”

Carcaño v. McCrory: Exhibit F - Hruz Declaration

Seen in: Carcaño v. McCrory

Endocrine Society/WPATH guidelines reflect advocacy, not consensus science

He argues that the clinical guidelines relied on to justify pediatric gender transition were written by a small, self-reinforcing group of WPATH-affiliated authors and rest on low-quality evidence, so they should not be treated as the product of independent scientific consensus.

“As directly stated in the Endocrine Society publication, “the strength of”

Carcaño v. McCrory: Exhibit F - Hruz Declaration

Seen in: Carcaño v. McCrory, Dekker v. Weida, Boe v. Marshall

Suicide-prevention rationale for treatment is unsupported

He argues that elevated suicidality among transgender patients persists after gender-affirming treatment, so claims that hormonal intervention is necessary to prevent suicide are not established by the evidence.

“social transition with or without surgical modification of external genitalia continue to have rates of depression and suicide far above the background population.”

Carcaño v. McCrory: Exhibit F - Hruz Declaration

“the adult literature consistently reports continued elevated suicidality after under-”

Dekker v. Weida: Exhibit Ex 13 Dr. Hruz Expert Report

Seen in: Carcaño v. McCrory, Dekker v. Weida, Boe v. Marshall

Social contagion / rapid-onset gender dysphoria

In his later reports he argues that the sharp rise in adolescent, especially female, gender-dysphoria referrals is better explained by a social-contagion process -- peer, school, and online influence -- than by an increase in an innate condition, a theory he did not articulate in his earlier declarations.

“The most recent evidence supports the emerging theory of social contagion as estimates of gender dysphoria-transgenderism are rocketing upwards from 1 in 10,000 to “the number of U.S. transgender-identified youth may be as high as 9%.””

Boe v. Marshall: Exhibit 5

“Currently the majority of new patients with”

Dekker v. Weida: Exhibit Ex 13 Dr. Hruz Expert Report

Seen in: Boe v. Marshall, Dekker v. Weida

How their positions have shifted

His earliest declaration in the record, Carcaño v. McCrory, argues primarily from desistance rates, fertility/irreversibility risk, adolescent brain plasticity, and inadequate informed consent -- it contains no social-contagion or 'rapid onset gender dysphoria' language and no critique of WPATH's authorship of the Endocrine Society guidelines as advocacy-driven. By the Boe v. Marshall report filed 2022-05-02, he has added an extensive social-contagion/ROGD argument (28 occurrences of 'social contagion') and citations to Abigail Shrier's book and the Tavistock/Bell v. Tavistock controversy. The 2023-2024 Dekker v. Weida report/declaration and the 2024 Boe supplemental report carry forward most of the 2022 Boe language nearly verbatim, including the detailed WPATH-membership critique of the Endocrine Society guideline panel, but the social-contagion discussion is comparatively compressed (6 occurrences in versus 28).

Under cross-examination

Their own answers in depositions.

Off-label prescribing in his own practice · Kadel v. Folwell (deposition exhibit filed in Dekker v. Weida)

Question (paraphrased): Asked whether he has personally ever prescribed any drugs on an off-label basis

“Very frequently do.”

Dekker v. Weida: Exhibit C - Deposition of Paul W Hruz
A source he cited · Boe v. Marshall

Question (paraphrased): Asked who Jesse Singal, whose article he cited in his report, is and what his background is

“I do not know. I can only objectively look at what was written in comparison to the actual data”

Boe v. Marshall: Exhibit Hruz Deposition Transcript

Testimony that travels

Sentences that appear word for word in their filings in different cases.

Curriculum vitae

Current positions

  • Associate Professor of Pediatrics, Endocrinology and Diabetes, Washington University in St. Louis (2011-present) source
    “Associate Professor of Pediatrics, Endocrinology and Diabetes”
  • Associate Professor of Pediatrics, Cell Biology & Physiology, Washington University in St. Louis (2011-present) source
    “Associate Professor of Pediatrics, Cell Biology & Physiology”
  • Associate Fellowship Program Director, Pediatric Endocrinology and Diabetes (2019-present) source
    “Associate Fellowship Program Director- Pediatric Endocrinology and Diabetes”

Education and training

  • BS, Chemistry, Marquette University, Milwaukee, WI (1987) source
    “BS, Chemistry, Marquette University, Milwaukee, WI”
  • PhD, Biochemistry, Medical College of Wisconsin, Milwaukee, WI (1993); dissertation on HMG-CoA lyase under Henry Miziorko source
    “PhD, Biochemistry, Medical College of Wisconsin, Milwaukee, WI”
  • MD, Medicine, Medical College of Wisconsin, Milwaukee, WI (1994) source
    “MD, Medicine, Medical College of Wisconsin, Milwaukee, WI”
  • Pediatric Residency, University of Washington, Seattle, WA (1994-1997) source
    “Pediatric Residency, University of Washington, Seattle, Washington”
  • Pediatric Endocrinology Fellowship, Washington University, Saint Louis, MO (1997-2000) source
    “Pediatric Endocrinology Fellowship, Washington University, Saint Louis, MO”
  • Certification in Healthcare Ethics, National Catholic Bioethics Center, Philadelphia, PA (2017) source
    “Certification in Healthcare Ethics, National Catholic Bioethics Center, Philadelphia, PA”

Past positions and roles

  • Locum Tenens Physician, Group Health of Puget Sound Eastside Hospital, Seattle, WA (1996-1997) source
    “Locum Tenens Physician, Group Health of Puget Sound Eastside Hospital, Group Health of Puget Sound Eastside Hospital, Seattle , WA”
  • Instructor in Pediatrics, Endocrinology and Diabetes, Washington University in St. Louis (2000-2003) source
    “Instructor in Pediatrics, Endocrinology and Diabetes, Washington University in St. Louis, St. Louis, MO”
  • Assistant Professor of Pediatrics, Endocrinology and Diabetes, Washington University in St. Louis (2003-2011); also Assistant Professor of Pediatrics, Cell Biology & Physiology (2004-2011) source
    “Assistant Professor of Pediatrics, Endocrinology and Diabetes, Washington University in St. Louis, St. Louis, MO”
  • Division Chief, Endocrinology and Diabetes, Washington University in St. Louis (2012-2017) source
    “Division Chief, Endocrinology and Diabetes, Washington University in St. Louis, St. Louis, MO”
  • Fellowship Program Director, Pediatric Endocrinology and Diabetes (2008-2016) source
    “Fellowship Program Director- Pediatric Endocrinology and Diabetes”
  • Consultant relationships with pharmaceutical companies Bristol Myers Squibb (1996-2012) and Gilead Sciences (1997-2012) source
    “Consultant, Bristol Myers Squibb”

Clinical practice

  • General Pediatrician, General Pediatric Ward Attending, St. Louis Children's Hospital: 2-4 weeks per year source
    “General Pediatrician, General Pediatric Ward Attending: 2-4 weeks per year, St. Louis Children's Hospital”
  • Pediatric Endocrinologist, Outpatient Endocrinology Clinic, St. Louis Children's Hospital: approximately 150 patient visits per month (2000-present) source
    “Pediatric Endocrinologist, Outpatient Endocrinology Clinic: Approximately 150 patient visits per month, St. Louis Children's Hospital”
  • Attending Physician, St. Louis Children's Hospital (2000-present) source
    “Attending Physician, St. Louis Children's Hospital”

Publications and research

  • Self-reported total of 60 scholarly articles published over his academic career, spanning more than two decades, in journals including Gastroenterology, Circulation, Diabetes, Science Signaling, Journal of Biological Chemistry, and FASEB Journal source
    “I have published 60 scholarly articles over my academic career spanning over two decades.”
  • Attached CV bibliography (as of 3/19/2023, Boe v. Marshall report) lists 52 numbered peer-reviewed journal articles (1992-2023), 3 book chapters, and 8 invited publications; early work (1992-2011) is on HMG-CoA lyase, GLUT1/GLUT4 glucose transporters, and HIV protease-inhibitor metabolic effects; later items (2017-2020) address gender dysphoria treatment, e.g. 'Growing Pains: Problems with Pubertal Suppression in Treating Gender Dysphoria' and 'The Use of Cross-Sex Steroids in Treating Gender Dysphoria' source
    “Hruz PW, Mayer LS, and McHugh PR. Growing Pains: Problems with Pubertal Suppression in Treating Gender Dysphoria The New Atlantis. 2017;52:3-36.”
  • Reports over $4.6 million in governmental and non-governmental research funding, including NIH, American Diabetes Association, American Heart Association, March of Dimes, and Harrington Discovery Institute grants source
    “I have received over 4.6 million dollars in governmental and non-governmental funding for scientific research including grants from the National Institutes of Health, the”

Licenses, boards, honors

  • Board Certified in General Pediatrics (1997-present) source
    “Board Certified in General Pediatrics”
  • Missouri medical license (2000-present); OCR of the CV renders the label 'State License' as 'Stae License' source
    “MO Stae License #2000155004”
  • Board Certified in Pediatric Endocrinology & Metabolism (2001-present) source
    “Board Certified in Pediatric Endocrinology & Metabolism”
  • Honors listed on CV: Phi Beta Kappa (1987), Alpha Omega Alpha (1994), Julio V Santiago M.D. Scholar in Pediatrics (2013), Redemptor Hominis Award for bioethics (2017), Eli Lilly Award for drug discovery (2018), Harrington Discovery Institute Scholar-Innovator Award (2018), Linacre Award (2021) source
    “Redemptor Hominis Award for Outstanding Contributions to the Study of Bioethics”

Disclosed compensation

  • Boe v. Marshall: $400 per hour source
  • Carcaño v. McCrory: $350 per hour source
  • Dekker v. Weida: $400 per hour source
  • Maxwell Kadel v. Dale Folwell: $400 per hour source

Testimony they lists themselves

  • Carcaño et al. v. Patrick McCrory 2016 · not specified in CV entry; separately documented as a declaration
  • Maxwell Kadel v. Dale Folwell 2021 · expert witness declaration (full text, filed under his own name)
  • Brandt v. Rutledge 2022 · not specified in CV entry (listed under 'Expert Witness Testimony')
  • Paul Eknes-Tucker v. Governor of the State of Alabama 2022 · expert report; caption evidence shows this case shares docket no. 2:22-cv-00184 with Boe v. Marshall

and 9 other matters they lists that are not in the litigation archive.

Sources and method

Built from the litigation archive: 14 excerpts of opinions and oral arguments and 7 court documents that name them, and 40 filings of their own. Every mention was checked for identity (2 mentions of other people with the same surname were set aside). Every quote on this page (60) was checked word for word against its source; 2 that did not match were left out. Profile version 1. Gaps: No report, declaration, or deposition text of Hruz's own is present in this folder for DOE v. LADAPO (payload are opposition briefs, not his own words) or for the 13-volume Eknes-Tucker filing (112897-112909); the DOE v. LADAPO role and the Eknes-Tucker/Boe docket-identity are established only from a court order (103847) and a co-plaintiff caption (102409), not from his own report. His own Kadel v. Folwell text (112194) survives only as an exhibit re-filed inside the Dekker v. Weida docket, so its Dekker-case attribution in payload.json reflects where the document was found, not the case it was written for -- this pattern (a report/declaration originally drafted for one case being re-filed as an exhibit in another) may recur elsewhere in these 89 documents and was not exhaustively checked beyond the four instances found (110944/101975/112069/112194 vs. the CV's self-reported case list, and 112194/112261/112262/112264/112265/112293 referencing Adams, Bruce, Whitaker, and Kadel depositions/declarations attached inside Dekker). None of Hruz's own compensation statements were found for DOE v. LADAPO or Eknes-Tucker specifically (both use the Boe v. Marshall / same-litigation documents where available). Kadel v. Folwell's own joint-appendix volumes (594, 595, 113313-113319) were not extracted as text, so that case's court characterization (112057, excluding much of his testimony) is not separately quoted here. No home address, phone, email, birth date, or family/patient names from the CV or reports were carried into this file, though the CV itself listed an office phone/fax and a personal email, and two self-reported cases (the 2019 Dallas custody matter and the Ohio school-board case) name minor children, which are quoted only by case caption, not by further identifying detail. Depositions were used only for cross-examination answers, not counsel's questions.

Back to the anti-trans experts